BIOCRATES Announces Launch of Metabolomics-based Bile Acids Kit
Complete the form below to unlock access to ALL audio articles.
BIOCRATES Life Sciences AG has announced the launch of the first-ever bile acids kit based on targeted metabolite quantitation. Recognized as endogenous markers for liver function, bile acids are essential for regulating cholesterol metabolism and the digestion and absorption of fat through the intestine.
Being transformed by the gut microbiota, bile acids can also function as signaling molecules in a wide range of metabolic processes related to a variety of disease situations. Bile-acid-mediated signaling via FXR and TGR5 receptors has been found to be essential in insulin expression and secretion, cardiovascular diseases, inflammation, and sepsis.
The signaling functions of bile acids can be used in the development of drugs for chronic disorders, such as obesity, type-2 diabetes mellitus, hypertriglyceridemia, or atherosclerosis.
Being aware of the essential role of bile acids, BIOCRATES Life Sciences has put its trusted competence in the development of mass-spectrometry-based kits to use and developed an assay for the standardized analysis of bile acids from as little as 10 µL human plasma (16 bile acids) or human serum and mouse plasma (19 bile acids) designed for research purposes.
The analyte panel of the BIOCRATES® Bile Acids Kit includes cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, hyodeoxycholic acid, muricholic acids as well as their glycine and taurine conjugates.
The BIOCRATES® Bile Acids Kit is based on (ultra) high performance liquid chromatography coupled with electrospray tandem mass spectrometry (UHPLC-MS/MS) and characterized by easy-to-perform, quick, and highly effective sample extraction on a 96-well patented filter plate.
To ensure accuracy and precision, the kit provides seven calibration standards, a mix of 10 isotope-labeled internal standards, and three levels of quality control samples. The assay has been rigorously validated in accordance with European Medicines Agency (EMA) guidelines.
Proficiency testing carried out in 10 different laboratories has demonstrated the kit’s excellent accuracy (85% to 115%) and precision (coefficient of variation< 20% for all target bile acids).
